Seres Therapeutics (MCRB) EBIT Margin (2016 - 2025)
Historic EBIT Margin for Seres Therapeutics (MCRB) over the last 9 years, with Q3 2025 value amounting to 6403.7%.
- Seres Therapeutics' EBIT Margin changed N/A to 6403.7% in Q3 2025 from the same period last year, while for Sep 2025 it was 29466.95%, marking a year-over-year increase of 1728814900.0%. This contributed to the annual value of 154.44% for FY2023, which is 23696100.0% up from last year.
- According to the latest figures from Q3 2025, Seres Therapeutics' EBIT Margin is 6403.7%.
- In the past 5 years, Seres Therapeutics' EBIT Margin registered a high of 53.98% during Q3 2021, and its lowest value of 57850.0% during Q4 2023.
- In the last 4 years, Seres Therapeutics' EBIT Margin had a median value of 1716.23% in 2022 and averaged 8085.74%.
- Over the last 5 years, Seres Therapeutics' EBIT Margin had its largest YoY gain of 52468100bps in 2023, and its largest YoY loss of -576724600bps in 2023.
- Seres Therapeutics' EBIT Margin (Quarter) stood at 684.56% in 2021, then soared by 74bps to 177.54% in 2022, then plummeted by -32484bps to 57850.0% in 2023, then surged by 89bps to 6403.7% in 2025.
- Its EBIT Margin was 6403.7% in Q3 2025, compared to 57850.0% in Q4 2023 and 14382.58% in Q3 2023.